Clinical Trial Update: Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) [Phase 3]

View source ↗

Summary

Phase 3 EXIST-1 trial evaluating everolimus for subependymal giant cell astrocytoma in tuberous sclerosis complex demonstrates efficacy and acceptable safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subependymal Giant Cell Astrocytoma
• Tuberous Sclerosis

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma | Phase 3 | Status: COMPLETED | Results posted: 2012-05-01